Ash A. Alizadeh
Stanford University
324 Papers
673 Citations
Ash A. Alizadeh is an academic researcher from Stanford University. The author has contributed to research in topics: Medicine & Biology. The author has an hindex of 69, co-authored 225 publications. Previous affiliations of Ash A. Alizadeh include National Institutes of Health & University of Miami.
Chat about Author
Papers
Circulating tumor DNA analysis for outcome prediction in localized esophageal cancer.
Tej D. Azad,Aadel A. Chaudhuri,Aaron M. Newman,Henning Stehr,Joseph G Schroers-Martin,Jacob J. Chabon,Penny Fang,Yawei Qiao,Zhongxing X. Liao,Ritsuko Komaki,Ash A. Alizadeh,Steven H. Lin,Maximilian Diehn +12 more
TL;DR: This data indicates that circulating tumor DNA (ctDNA) is an attractive biomarker that could be used in clinical practice in patients with esophageal carcinomas.
3
Utility in prognostic value added by molecular profiles for diffuse large B-cell lymphoma.
TL;DR: The conclusions that gene expression signatures are inferior to clinical factors and provide little added prognostic value in diffuse large B-cell lymphoma were surprised.
3
Recurrent Crebbp Mutations in Follicular Lymphoma Appear Localized to the Committed B-Cell Lineage
Joseph G Schroers-Martin,Joanne Soo,Gabriel Brisou,Florian Scherer,David M. Kurtz,Brian Sworder,Michael S. Khodadoust,Michael C. Jin,Agnès Bru,Chih Long Liu,Henning Stehr,Paolo Vineis,Yasodha Natkunam,Bertrand Nadel,Maximilian Diehn,Sandrine Roulland,Ash A. Alizadeh +16 more
TL;DR: HSCs are believed to be the cell of origin in several lymphoid leukemias, and mouse models have demonstrated lymphoma development with induced CREBBP lesions in HSCs (Horton et al Nat Cell Bio 2017), which raises the possibility that such early lesions could occur in hematopoietic stem cells (H SCs) rather than in the committed B-cell lineage.
3
Mrd‐negativity after frontline dlbcl therapy: pooled analysis of 6 clinical trials
Mark Roschewski,David M. Kurtz,Jason R. Westin,Ryan C. Lynch,Stefan Alig,Charles Macaulay,Christian Kuffer,Gregory J. Hogan,Andre Schultz,Sandra Close,Jacob J. Chabon,D. Rossi,Stephen Opat,Rod Hicks,Mark Hertzberg,Maximilian Diehn,Walter Walter Wilson,Ash A. Alizadeh +17 more
TL;DR: Kurtz et al. as mentioned in this paper integrated PhasED-Seq MRD from LBCL studies using curative intent 1st-line regimens to predict future PFS events, with lead times up to 30 mo before radiologic PD.
2